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Background: Unwarranted administration of antibiotics in acute pancreatitis presents a global challenge.
The clinical reasoning behind the misuse is poorly understood. Our aimwas to investigate current clinical
practices and develop recommendations that guide clinicians in prescribing antibiotic treatment in acute
pancreatitis.
Methods: Four methods were used. 1) Systematic data collection was performed to summarize current
evidence; 2) a retrospective questionnaire was developed to understand the current global clinical
practice; 3) five years of prospectively collected data were analysed to identify the clinical parameters
used by medical teams in the decision making process, and finally; 4) the UpToDate Grading of Rec-
ommendations, Assessment, Development and Evaluation (GRADE) system was applied to provide evi-
dence based recommendations for healthcare professionals.Antibiotic therapy in acute pancreatitis: From global overuse to evidence based recommendations,
.2019.04.003
A. Parniczky et al. / Pancreatology xxx (xxxx) xxx 3Please cite this article as: Parniczky A et al.,
Pancreatology, https://doi.org/10.1016/j.pan.Results: The systematic literature search revealed no consensus on the start of AB therapy in patients
with no bacterial culture test. Retrospective data collection on 9728 patients from 22 countries indicated
a wide range (31e82%) of antibiotic use frequency in AP. Analysis of 56 variables from 962 patients
showed that clinicians initiate antibiotic therapy based on increased WBC and/or elevated CRP, lipase and
amylase levels. The above mentioned four laboratory parameters showed no association with infection in
the early phase of acute pancreatitis. Instead, procalcitonin levels proved to be a better biomarker of early
infection. Patients with suspected infection because of fever had no benefit from antibiotic therapy.
Conclusions: The authors formulated four consensus statements to urge reduction of unjustified anti-
biotic treatment in acute pancreatitis and to use procalcitonin rather than WBC or CRP as biomarkers to
guide decision-making.
© 2019 IAP and EPC. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
There is a general overuse of antibiotics (ABs) worldwide
resulting in AB resistance, which is part of the most remarkable
hazards to global health [1]. The misuse of AB has been associated
with fungal infection, Clostridium difficile infection and increased
costs [2,3]. In 2009, approximately $10.7 billion was spent on
antibiotic therapy in the United States (US), including $6.5 billion in
the outpatient, $3.6 billion in acute inpatient care, and $526.7
million in long-term care settings [4]. According to the latest report
from Germany, the total amount of antimicrobials used in human
medicine is estimated to range between 700 and 800 tonnes per
year [5], 15% of its used by hospitals, while 85% in primary practice
[6]. European Surveillance of Antimicrobial Consumption Networks
report that antibiotic-resistant bacteria claim lives of approxi-
mately 700000 people each year globally [7]. The annual impact of
resistant infections is estimated to be $20 billion in excess health
care costs and 8 million additional hospital days in the US [8e10]
and over 1.6V billion and 2.5 million additional hospital days in the
European Union (EU) [11]. Antimicrobials currently account for
over 30% of hospital pharmacy budgets in the US [12].
The administration of ABs in acute pancreatitis (AP) has been
widely and thoroughly investigated [13]. We must note that either
direct pathologic insult of the pancreas i.e., alcohol, bile or fatty
acids [14], or increased autoactivation of trypsinogen [15] without
infection can activate inflammatory pathways, therefore AP itself is
not an indication for AB therapy [16,17]. Notably, current guidelines
do not recommend prophylactic AB therapy for the prevention of
infectious complications in AP (IAP/APA guideline, Grade 1B) [18],
(American College of Gastroenterology, strong recommendation,
moderate quality of evidence) [19]. However, in cases of proven
source of infection empiric administration of ABs is justified [20].
Based on the above mentioned suggestions we can calculate the
rate of ABs should be used in AP: pancreatic infection is a rare event
in AP (around 5%) [21], moreover there is only 14%e37.4% extra-
pancreatic indications (such as cholangitis or pneumonia) are re-
ported [22e25], therefore, the justified rate of ABs use should be
between 20 and 40% in AP.
However, the Hungarian Pancreatic Study Group (HPSG) found
that 77.1% of the total study population (n¼ 600) received AB
therapy and two thirds of this group had no signs of infection,
meaning AB treatment was administered on a preventive basis [25].
In population-based studies,14% of patients received unjustified (so
called prophylactic) AB in Portugal [26], 25.5% in Canada [27],
27e58% in the USA [28], 30.7% in the UK [23], 81.4% in India [29],
44.6e69.3% [30] and 74.3% in Japan [31].
There could be several reasons behind AB overuse worldwide:
1) The guideline is insufficient regarding AP therapy. It only states
that intravenous AB prophylaxis is not recommended for the pre-
vention of infectious complications in AP (GRADE 1B, strongAntibiotic therapy in acute pa
2019.04.003agreement), failing to offer indication for proper AB treatment [18].
2) Misinterpretation of inflammatory biomarkers, such as C reac-
tive protein (CRP) during AP [26]. It has been suggested that
elevation of CRP can have major influence on prescribing prophy-
lactic ABs in AP [26]. 3) Non-adherence to guidelines [13]. Several
studies reported moderate or non-compliance to the recommen-
dations for the management of AP [23,27,29,32e36]. 4) Defensive
medical care in which healthcare providers try to protect them-
selves from malpractice claims [37e39].
These data clearly suggest the crucial importance of multicentre,
multinational studies aiming to give proper recommendations for
AB utilization in AP.
The specific aims of this study were to (1) summarize current
evidence, (2) understand the current global practice, (3) under-
stand the clinical parameters used bymedical teams in the decision
making process, (4) verify the usefulness of these parameters, (5)
make more informed recommendations for healthcare
professionals.Methods
1. Systematic review
The systematic review aimed to summarize the recent evidence
(1) on the guidance of AB therapy and (2) on the strategies how
high-quality studies raised the suspicion of pancreatic infection in
AP. We observed the rules of Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses (PRISMA) 2009 guideline
when reporting this work [40].Eligibility
Eligible randomized controlled trials (RCTs) discussed (1) pa-
tients diagnosed with AP (2) who were given any ABs orally and/or
intravenously (3) with available full-text of any languages. Studies
applying continuous regional arterial infusion or other drugs (e.g.,
protease inhibitors) were excluded. We chose the inclusion of RCTs
on the guidance of AB therapy or preventive AB therapy because
high-quality studies centered around the suspicion of pancreatic
infection are lacking. Our assumption that the best evidence on the
topic might be present in these studies relies on two arguments. On
one hand, definitive infection and infected pancreatic necrosis are
high-priority hard outcomes of these studies focusing on infection
control. On the other hand, suspicion of infection is a safety issue in
these studies because of the required immediate intervention, such
as a change in per protocol drug regime or a surgical/radiological
approach.ncreatitis: From global overuse to evidence based recommendations,
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We searched cited and citing articles, including previous meta-
analysis and systematic reviews, of relevant reports for eligible
studies. We did not contact the authors of original studies for
information.
We conducted a comprehensive systematic search in MEDLINE
(PubMed), EMBASE, and Cochrane Trials from inception up to 7 July
2018 for articles reporting on the use of antibiotics in AP. We
applied the following query without any filters imposed on the
search: pancreatitis AND (antibiotic OR antibiotics OR carbapenem
OR imipenem OR meropenem OR ertapenem OR doripenem OR
aminoglycoside OR amikacin OR gentamicin OR cephalosporin OR
cefepime OR ceftriaxone OR ceftazidime OR cefoperazone OR
cefixime OR cefuroxime OR cephalexin OR ceftobiprole OR cefa-
zolin OR cefalotin OR glycopeptide OR vancomycin OR teicoplanin
OR penicillin OR amoxicillin OR ampicillin OR oxacillin OR piper-
acillin OR mezlocillin OR ticarcillin OR sulbactam OR tazobactam
OR clavulanate OR fluoroquinolone OR ciprofloxacin OR levo-
floxacin OR moxifloxacin OR ofloxacin OR pefloxacin OR metroni-
dazole OR tigecycline OR linezolid OR daptomycin).
Yield of search was combined in reference manager software
(EndNote X7.4, Clarivate Analytics, Philadelphia, PA, US) to remove
overlaps between databases and duplicates, then, two independent
investigators screened the records by title, abstract, and full-texts
against our eligibility criteria in duplicate. Discrepancies were
resolved by third party arbitration.
Data collection
A pre-constructed data collection table was designed by our
research team. After this step, training was organized to increase
the consistency of data collection. Data were extracted by two in-
dependent review authors in duplicate. Discrepancies were
resolved by a consensus meeting of our research team.
The following data were extracted: publication data (authors,
year), setting (country, centres, setting), definition and etiology of
AP, eligibility criteria of the study, the total number of patients (in
intention to treat and per protocol analyses), and interventions
(drug regimens and/or guidance of therapy). In addition, definitions
of suspected and definitive pancreatic and extrapancreatic in-
fections, and the consequent clinical management were collected.
2. Retrospective data analysis
To assess the worldwide trends in administration of AB we sent
a letter of invitation and a questionnaire to the member of the In-
ternational Association of Pancreatology in November 2017. Col-
leagues have provided data from their past-year inpatients’ practice
accordingly to gender, etiology, mortality and severity of AP, and AB
therapy irrespectively from its indication. Percentage of AB treat-
ments was calculated, and it has been illustrated on a colour scaled
map.
3. Prospectively collected data analysis
The Hungarian Pancreatic Study Group (HPSG) (https://tm-
centre.org/en/study-groups/hungarian-pancreatic-study-group/)
was established in 2011 with the aim to improve patients’ care in
pancreatic disease. We have developed an international, uniform
and prospective electronic data registry to collect high quality data
from patients suffering from AP. From January 1, 2013 to November
30, 2016, 1070 episodes of AP have been enrolled. Centre distri-
bution is indicated in Supplementary Fig. 1. Diagnosis of AP was
based on the A1 recommendation of the IAP/APA guideline. Two ofPlease cite this article as: Parniczky A et al., Antibiotic therapy in acute pa
Pancreatology, https://doi.org/10.1016/j.pan.2019.04.003the following alterations were confirmed in each patient: abdom-
inal pain (clinical symptom), pancreatic enzyme elevation at least
three times above upper limit andmorphological changes (imaging
techniques).
Four quality control points were established in our registry. First,
the local clinical research assistant electronically uploads the data
and confirms equivalency with the hard copy. Second, the local
institutional principal investigator (who holds a medical doctoral
degree) double-checks the uploaded data and confirms the validity
and accuracy. Third, the central data administrator, who is based at
the headquarters of HPSG, controls the accuracy and finally (in
house monitor), the registry leader reviews the presented data and
verifies them. Patients with inadequate or insufficient data are
excluded.
To answer our post hoc defined research question, data from
HPSG pancreatic registry were analysed. We selected 56 parame-
ters relating to our research question (Supplementary Fig. 2.). Those
patients’ data were used for further analysis where the following
information were available in its entirety: age, gender, length of
hospitalization, severity, based on revised Atlanta classification,
mortality, complications and details about AB therapy (starting
date, type of antibiotics, etc.) [17]. Data of 962 patients met the
criteria mentioned above, so this cohort was used for further
analysis.
The following groups have been designated. Patients in Group1
and 2 did not receive AB therapy. Patients in Group 1 did not receive
AB therapy and their no symptoms or evidence of infection. Pa-
tients in Group 2 did not receive AB treatment either, however,
there were symptoms which may associated with infection (ie.
fever) or the followings were declared: positive bacterial culture,
cholangitis, upper or lower respiratory tract infection, urogenital
infection, and infection of any other organ system.
Members of Group 3, 4 and 5 all received AB treatment. In Group
3, patients had no features characteristic of infection, therefore
received AB as prevention. In these patients there were no signs of
infection or negative bacterial culture. Patients in Group 4 received
empirical AB therapy since they had features characteristic of
infection (with no (a) or negative bacterial culture (b)). Group 5
patients took AB as a targeted therapy following positive bacterial
culture, specifying the exact cause of infection and/or gas in and/or
around the pancreas on CECT or MRI.
Statistical analysis
For descriptive statistics, the number of patients, mean, stan-
dard deviation (SD), standard error of mean (SEM), minimum,
median and maximum values were calculated for continuous var-
iables, and the case number and percentage were computed for
categorical values.
For inferential statistics, the following tests were applied to
determine statistical significance of differences between groups. To
compare two groups of independent samples, the t-test was used
for normally distributed data and the Mann-Whitney U test for
non-normally distributed data. To compare more than two groups,
one-way ANOVA followed by the Tukey post hoc test was employed
for normally distributed data with homogenous group-wise stan-
dard deviation; Brown-Forsythe Levene-type test was applied to
test of variance homogeneity; the Welch test followed by the
Games-Howell post hoc test for normally distributed data with
heterogeneous group-wise standard deviation; and the Kruskal-
Wallis test followed by the Holm p-value adjustment method for
non-normally distributed data.
The association between categorical variables was inspected by
the Chi-square test and Fisher's exact test. To compare proportions
for more than two groups, the pairwise proportion test followed byncreatitis: From global overuse to evidence based recommendations,
A. Parniczky et al. / Pancreatology xxx (xxxx) xxx 5the Holm p-value adjustment was used. The level of statistical
differences were defined in all cases.
The relevant statistical tests are also described in the legends to
the figures. Statistical analyses were performed using SPSS (Version
23, IBM, New York, NY, USA) and R Studio (Version 1.1.453, fmsb
package).
The authors have read the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) State-
mentdchecklist of items, and the manuscript was prepared and
revised accordingly [41].
4) Development of evidence based recommendationsGrading
Strength of recommendation and quality of evidence were
based on the guideline of the Grading of Recommendations
Assessment, Development and Evaluation (GRADE) Working
Group, an internationally accepted system established in 2011
(https://www.uptodate.com/home/grading-tutorial#). Strength of
any recommendation depends on the establishment between
benefits and risks and burden. Three-category has been imitated for
quality of evidence regarding treatment effect. All authors deter-
mined the strength of the consensus by voting yes or no: 95% or
more ‘yes’ votes¼ ‘full agreement’; at least 70% ‘yes’ votes¼ ‘strong
agreement’, and more than 50% ‘yes’ votes¼ ‘weak agreement’.
5) Ethics
The study was approved by the Scientific and Research Ethics
Committee of the Medical Research Council (22254e1/2012/EKU).
All participants provided written consent of participation to this
study. The ethics committee carefully checked and approved the
consent procedure.
Results
There is no consensus on the start of AB therapy in patients with no
bacterial culture test
Supplementary Figure 3 shows the flowchart of this systematic
review. After careful selection, only 1 RCT reporting on the guidance
of AB therapy was eligible for inclusion [42]. In this study, pro-
calcitonin (PCT)-guided (>0.5 ng/ml) AB regime proved to be su-
perior over 2-week prophylactic AB treatment in severe AP
(Supplementary Fig. 4). We identified 22 studies [42e63] reporting
on prophylactic antibiotic treatment in AP. Severe AP/acute necro-
tizing pancreatitis were analysed in 18 of 22 studies, however, these
entities were defined in many forms: 9 and 11 studies incorporated
CRP (ranging from >100 to >200mg/l) and pancreatic necrosis
(confirmed by CT or FNA) into the definitions Supplementary Fig. 5.
Despite the inclusion of RCTs, the way how the studies defined the
suspicion of an infection was vague. Factors taken into consider-
ationwere, as follows: CRP (5 studies), fever (generally in 5 studies,
2 of them considered persistent fever only), criteria of SIRS/organ
failure/sepsis (3 studies), air bubbles in necrosis on CT (2 studies),
and leukocytosis (2 studies). Only 2 studies suspected an infection
when a rise in inflammatory markers occurred following an initial
decrease. Interestingly, neither of the studies testing prophylactic
ABsmentioned PCT, as amarker of infection in the included studies.
The general approach proved a suspected infection was FNA and
culturing in most cases followed by surgery as a treatment. A
change in drug regime was managed either empirically and/or by
culturing.Please cite this article as: Parniczky A et al., Antibiotic therapy in acute pa
Pancreatology, https://doi.org/10.1016/j.pan.2019.04.003Antibiotics are overused worldwide
9869 patients’ data were collected from 23 countries and it
showed a global overuse of ABs. The highest rates of AB therapy
could be seen in Asia (China 81.4%, Taiwan 80.6%) and Eastern
Europe (Albania 78.6%, Bulgaria 78%), whereas the lowest rates are
observed in Western Europe (Spain 31.8%, United Kingdom 31.2%)
(Fig. 1). There is no association between the rate of AB therapy and
the outcome (mortality, severity) of the disease between the
countries. The details of centres and countries can be found in
Supplementary Fig. 6.
There is a large detection bias in the initiation of AB therapy and
bacterial culture test
In these series of data analysis we aimed to understand the
decision making process of physicians concerning the initiation of
AB therapy in AP. 962 of 1070 prospectively collected patients in the
HPSG AP registry had details concerning AB therapy. Firstly, we
confirmed that the registry represents a normal distribution of AP
concerning age, gender, etiology, length of hospitalization (LOH),
severity and mortality (Supplementary Fig. 7). Secondly, we per-
formed the analysis on the major outcome parameters (LOH,
severity and mortality) and found that (i) worse LOH, severity and
mortality parameters are associated with AB treatment, (ii) holding
off the AB therapy among patients with suspected infection (Group
2) is not associated with poor outcome, (iii) patients having bac-
terial culture (Group 4b) test had significantly worse outcome than
patients having no bacterial test (Group 4a) among AB treated
groups, (iv) confirmed infection had the worst outcome in AP
(Group 5) (Fig. 2A and B) (v) the willingness of the initiation of AB
therapy elevates parallel with the severity and finally (vi) the
highest level of AB therapy is in biliary AP (Fig. 2C).
90% of AB therapy started in the first 3 days of AP
74% of AB are started on Day 1, 10.5% on Day 2, whereas 6.0% on
Day 3 (Supplementary Fig. 8A). Early AB treatment had no associ-
ation either with shorter AB administration (Supplementary
Fig. 8D), or with the outcome of AP (Supplementary Figs. 8E and
J). Administration of three different ABs (Supplementary Figs. 8B,
F, G, K) or higher number of changes in the AB regime
(Supplementary Figs. 8C, H, I, L) are associated with longer AB
therapy and worse outcome of the disease suggesting that if pa-
tients’ condition do not improve during AB therapy or bacterial
resistance occurs doctors initiate AB therapy changes. Detailed
statistics can be found in Supplementary Fig. 9. In 52% of the cases
single AB, in 43.7% double AB, whereas in 4.3% three or more AB
were administered. In the single AB group cephalosporin 29.5%,
whereas in the double AB group ciprofloxacin and metronidazole
were the most commonly chosen therapies (Supplementary
Fig. 10). Of course a cohort analysis is not enable to differentiate
between the drugs, but not surprisingly imipenem or not conven-
tional AB therapies were associated with more severe pancreatitis
and higher mortality (Supplementary Fig. 10). Detailed statistics
can be found in Supplementary Fig. 11.
Elevated CRP level, white blood cell (WBC) count, lipase and amylase
levels are the biomarkers used for the initiation of AB therapy
We investigated the four most commonly monitored laboratory
markers (amylase, lipase, C-reactive protein, WBC count) during
the course of AP. Mean levels of these parameters on the starting
day of AB therapy were compared. The amylase and lipase levels
showed association with the AB treatment, but as we expected, notncreatitis: From global overuse to evidence based recommendations,
Fig. 1. Map of antibiotic use worldwide. There is a general overuse of AB worldwide (57.2%). The highest rates of AB therapy are in Asia (China 81.4%, Taiwan 80.6%) and Eastern
Europe (Albania 78.6%, Bulgaria 78%), whereas the lowest rates are observed in Western Europe (Spain 31.8%, United Kingdom 31.2%).
Fig. 2. Grouping of patients based on sign of infection, antibiotic (AB) treatments and microbiology examination. General characterisation of AB administration, length of
hospitalization (LOH) and mortality. Based on the AB treatment patients were divided into two main groups (non-AB and AB) and six subgroups. Group 1: Patients had no sign of
inflammation and did not received ABs. Group 2: Patients had sign of inflammation (fever, imaging alterations, etc.) but did not received ABs. Group 3: Patients had no sign of
inflammation but received preventive ABs. Group 4a: Patients had sign of inflammation (fever, imaging alterations, etc.) and received antibiotics, however no microbiology culture
was requested. Group 4b: Patients had sign of inflammation (fever, imaging alterations, etc.) and received antibiotics. Microbiology culture was done but no pathogen bacteria were
found. Group 5: Patients had sign of inflammation (fever, imaging alterations, etc.), microbiology culture was performed with positive results and received AB treatment. A. LOH was
significantly longer in AB therapy groups then in non-AB groups. (13.4± 0.5 days vs 8.3± 0.3 days, p< 0.001) In presence of suspected infection (Group 2) LOH (8.3± 0.4 days vs
8.2± 0.4 days), severity and mortality were the same as in Group 1. Preventive AB therapy (Group 3) resulted significantly longer hospitalization compare to Group 1 (12.3± 1.1 days
vs 8.3± 0.4 days, p< 0.001). Significantly more patients with moderate (220/718 vs 46/244, p< 0.001) and severe disease (50/718 vs 3/244, p< 0.001) course received AB therapy.
There was no significant difference in mortality between the groups. B. If we retracted Group 5 (patients with proven infection), the rate of AB therapy still remained significantly
high in moderate and severe AP (p< 0.001, p¼ 0.023). C. AB treatment in context of etiology of AP.
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A. Parniczky et al. / Pancreatology xxx (xxxx) xxx 7with the severity of the disease (Fig. 3AeB, E-F). In addition,
significantly higher inflammatory markers (CRP and WBC) were
associated with the AB treatment and more severe AP (Fig. 3CeD,
G-H).
Elevation of PCT level but not CRP, WBC, lipase or amylase levels are
associated with infection in the early phase of AP
CRP levels progressively increase, whereasWBC values decrease
during the first 3 days of AP irrespectively of AB therapy in either
suspected (Group 4a and b) or in confirmed (Group 5) infection (Fig
4A, F). Suspected infection (Group 2) did not show difference in CRP
and WBC levels compared to Group 1 among the non-AB groups
(Fig. 4B, G). Preventive AB therapy (Group 3) was administered in
patients with significantly higher CRP and WBC levels (p< 0.001,
p¼ 0.046), however, both CRP and WBC level decreased nearly the
same level as Group 1 by day 5 (Fig. 4C, H). Bacterial culture test
(Group 4b) was performed in patients with significantly higher CRP
(p¼ 0.008) (Fig. 4D). These data are in accordance with the results
at the start of AB therapy in AP (Fig. 3.). Very importantly, neither
CRP nor WBC showed differences between patients having positive
blood culture (Group 5) vs. patients having negative blood culture
tests (group 4b), suggesting that CRP and WBC have no association
with infection at the early phase of AP (Fig. 4E, J, L, M). However,
PCT level, as confirmed in earlier studies showed correlation with
infection (Fig. 4K, N) with acceptable sensitivity and specificityFig. 3. Most commonly monitored laboratory markers on starting day of AB therapy.
calculated on starting day of AB therapy. In non-AB groups day-matched controls were sel
(1004.15± 50.22 U/L) has been significantly differed (p< 0.001). B. There has been a significa
(2298.72± 207.82 U/L) groups. C. CRP showed a significant difference between non-AB and
detected with regards to WBC levels (10.32 ± 0.28 G/L vs 13.8± 0.2 G/L, p< 0.001 (D). E. Aver
(2303.05 ± 219.19 U/L, 2286.82 ± 378.21 U/L, 2131.42± 1377.75 U/L) did not differ between s
G. Average CRP (68.77± 4.32mg/L, 104.56± 8.71mg/L, 181.7± 27.26mg/L) and WBC (H) (12.8
AP (mild-moderate: p¼ 0.007 and p< 0.001, moderate-severe: p¼ 0.012 and p¼ 0.22).
Please cite this article as: Parniczky A et al., Antibiotic therapy in acute pa
Pancreatology, https://doi.org/10.1016/j.pan.2019.04.003(AUC:0.73). Fig. 5 shows the changes of amylase and lipase during
AP. It is very clear that neither infection (Group 2) nor AB treatment
(Group 3, 4 and 5) change the pattern of enzyme levels during AP.Pancreatic infection causes the worst outcome in AP
Here we correlated the disease outcome with the infected or-
gans. Biliary, respiratory, urogenital infection or elevated PCT or
fever alone with no identified organ infection resulted in a mod-
erate severity range (8.3%e14.3%) without mortality, however
pancreatic infection caused 25% severe AP with extremely high
mortality rate (25%), (Fig. 6). Detailed statistics can be found in
Supplementary Fig. 12.Increase in the pathogen numbers is associated with the worse
outcome of AP
The most common pathogens were Staphylococci (34.2%),
Enterococci (27.4%), Clostridium difficile (22.4%), Escherichia coli
(18.4%) and Pseudomonas (13.2%). Due to the relatively low event
rates, we could not analyse the differences among pathogens,
however, it was obvious that increased numbers of detected
pathogens strongly correlates with worse outcomes in AP
(Supplementary Fig. 13).Average amylase, lipase, C-reactive protein (CRP) and white blood cells (WBC) were
ected. A. Average amylase in non-AB group (510.01± 57.91 U/L) compare to AB group
nt difference (p < 0.001) between average lipase in non-AB (815.83± 96.73 U/L) and AB
AB groups (52.16± 4.91mg/L vs 86.4 ± 4.2mg/L, p< 0.001) similar trends have been
age amylase (1015.25± 55.10 U/L, 957.41± 83.33 U/L, 1077.48 ± 397.02 U/l and lipase (F)
everity groups (mild-moderate: p¼ 0.26, p¼ 0.16; moderate-severe: p¼ 0.16, p¼ 0.15).
3 ± 0.21 G/L, 15.11± 0.49 G/L, 16.5± 0.98 G/L) levels showed correlation with severity of
ncreatitis: From global overuse to evidence based recommendations,
Fig. 4. Trends in the changes of CRP and WBC during the early phase of AP. A. Due to the inflammation of the pancreas, irrespectively from the infection CRP levels rose during
the first 3 days. F. Non-similar trend can be seen in WBC levels. B and G. Suspected infection (Group 2) in AP did not show difference (p¼ 0.431, p¼ 0.923) in cumulative average
(cAVE) of CRP (70.33± 6.31mg/L) and cAVE of WBC levels (10.82± 0.47 G/L) compare to Group 1 (57.12± 5.50 U/L, 10.14± 0.29 G/L). C and H. Preventive AB therapy (Group 3) was
administered in patients with significantly higher CRP (104.69± 8.05mg/L) and WBC levels (11.71± 0.40 G/L) (p¼<0.001 and p¼ 0.046, respectively), however we observed the CRP
increase, then drop at day 3 and decreased nearly the same level as Group 1 by the day 5. D and I. Bacterial culture (Group 4b) was performed in patients with significantly higher
CRP (102.90 ± 3.88mg/L vs 141.05± 8.66, p< 0.001). E. and J. Proven infection (Group 5) did not result in significant difference in CRP andWBC levels in the first five days. K: cAVE of
PCT differ significantly between Group 4b and Group 5 (p¼0.026). L, M and N. CRP (AUC: 0.51) and WBC (AUC: 0.45) failed, however PCT (AUC: 0.73) fairly can predict infection in
AP.
A. Parniczky et al. / Pancreatology xxx (xxxx) xxx8Consensus statements
Based on the systematic review and retrospective and pro-
spective data analysis, the authors from 62 centres/23 countries
accepted the following statements and recommendations as
amendments to the current guidelines (Table 1.)Please cite this article as: Parniczky A et al., Antibiotic therapy in acute pancr
Pancreatology, https://doi.org/10.1016/j.pan.2019.04.003Statement 1: There is a general overuse of ABs in AP, therefore,
centres should make a strong effort to reduce it to a justifiable
level (GRADE 1C: strong suggestion, low quality evidence, full
agreement)
Statement 2: CRP and WBC values are not associated with
infection in the early phase of AP, therefore CRP andWBC should
not be used as biomarkers for decision making concerning ABeatitis: From global overuse to evidence based recommendations,
Fig. 5. Trends in the changes of amylase and lipase during the early phase of AP. There are no significant differences between the groups.
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Patherapy in the early phase of AP (GRADE 1C: strong suggestion,
low quality evidence, full agreement).
Statement 3: Progressive elevation of CRP is part of the in-
flammatory response in AP, therefore, an upward trend of CRP
levels should not be an indicator for AB treatment in the early
phase of AP (GRADE 1C: strong suggestion, low quality evidence,
full agreement).
Statement 4: Elevation of PCT levels during the early phase of
AP is associated with infection, therefore, it can guide the choice
to start AB treatment in the absence of proven infection (GRADE
2C: weak suggestion, low quality evidence, full agreement).Discussion
At the beginning of our study, we performed a systematic re-
view in which we showed that (i) PCT can be a good marker for
suspected infection (ii), there is no consensus concerning the
compulsory start of AB therapy in patients with no positive bac-
terial culture test, (iii) patients having necrosis have no benefits
from AB therapy. These data have predicted the results of our in-
ternational retrospective data analysis, which showed that
administration of ABs widely differs between countries.ease cite this article as: Parniczky A et al., Antibiotic therapy in acute pa
ncreatology, https://doi.org/10.1016/j.pan.2019.04.003Generally, in Western European countries less AB is adminis-
tered, whereas Eastern European and Asian countries are the most
frequent users of AB. Our data are in accordance with several na-
tional surveys performed in the past two decades. In Germany, 47%
of respondents use AB prophylaxis [32] and 44% of the doctors al-
ways administer AB in cases of severe AP [33]. In the UK and
Ireland, 24% use prophylaxis in AP regardless of the severity [64].
Prophylactic AB treatment is utilized by 73% of the European
members of the International Hepato-Pancreato-Biliary Association
[65]. 40.9% of the interviewed American clinicians give AB in more
than 75% of patients with severe AP [35]. In Japan, before the
publication of the Japanese evidence-based guidelines in 2003,
82.5% of the physicians used AB prophylaxis after the publication
76.1% [34], which is still a frequent practice pattern, considering
that the Japanese guidelines also endorse routine use of AB pro-
phylaxis in mild to moderate AP [66,67]. These data show without
proper guideline, the physicians’ willingness of AB therapy is very
high. The high rate of AB treatment can also be explicable with the
fact that the death rate can increase from 2 to 35% due to bacterial
infection of the necrotic pancreatic tissue [25,68] Organ failure
alone was associated with a mortality of 19.8% [68,69], whereas,
infected necrosis without organ failure has low mortality [70].
Based on these observations, it is not surprising that several trialsncreatitis: From global overuse to evidence based recommendations,
Fig. 6. Source of infection in AP. Infection of the pancreas extended the length of hospitalization (LOH) to 25.55± 4.76 days, deteriorated the course of the disease (moderate 25%,
severe 75%) and elevated the mortality to 25%. PIe charts represent the distribution of mild (green), moderate (yellow) and severe (red) cases in each group of AP patients.
Table 1





1 There is a general overuse of antibiotics in AP, therefore, centres should make a strong effort to reduce it to a justifiable level. 1C full (99%)
2 CRP andWBC values are not associated with infection in the early phase of AP, therefore CRP andWBC should not be used as biomarkers
for decision making concerning AB therapy in the early phase of AP.
1C full (97%)
3 Progressive elevation of CRP is part of the inflammatory response in AP, therefore, an upward trend of CRP levels should not be an
indicator for AB treatment in the early phase of AP.
1C full (97%)
4 Elevation of PCT levels during the early phase of AP is associated with infection, therefore, it can guide the choice to start antibiotic
treatment in the absence of proven infection.
2C full (96%)
A. Parniczky et al. / Pancreatology xxx (xxxx) xxx10and meta-analysis were performed to understand the usefulness of
preventive AB in AP [44,49,53,54,56,57,59,61,71]. A recently pub-
lished Cochrane review showed that neither of the preventive AB
treatments decreased short-term mortality in AP [72].
The most important goals of our study were (i) to find out whatPlease cite this article as: Parniczky A et al., Antibiotic therapy in acute pa
Pancreatology, https://doi.org/10.1016/j.pan.2019.04.003parameters mislead physicians during the initiation of AB therapy
(ii) to find a biomarker(s), which can predict infection without
bacterial culture test. In this investigation we showed with several
analysis that elevation of amylase, lipase levels, CRP and WBC
mislead the doctors decisionmaking on the initiation of AB therapy.ncreatitis: From global overuse to evidence based recommendations,
A. Parniczky et al. / Pancreatology xxx (xxxx) xxx 11CRP and WBC have been confirmed to be strongly associated with
the severity of AP [73e75] however, data on lipase and amylase are
contradictory [76e79]. In our study, the initiation of AB therapy
was based on the severity and most probably on a predicted
infection diagnosed by the elevation of inflammatory biomarkers
namely the CRP andWBC. Here we confirmed that these laboratory
parameters have no association with infection, but PCT, which
showed correlation with infection with acceptable sensitivity and
specificity.
Finally, based on the systematic review and the retrospective
and prospective cohort analyses, the participants of this trial
accepted important statements and recommendations as amend-
ments to the current guidelines. The authors strongly believe that
the evidence and consensus statements presented in this article
will significantly decrease unnecessary AB therapy in AP
worldwide.
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